ENTRY       D10525            Mixture   Drug
NAME        Valsartan and cilnidipine;
            Atedio (TN)
COMPONENT   Valsartan [DR:D00400], Cilnidipine [DR:D01173]
CLASS       Cardiovascular agent
             DG01925  Renin-angiotensin system inhibitor
             DG03231  Antihypertensive
            Metabolizing enzyme substrate
             DG01639  CYP2C19 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 2149
            Product: D10525<JP>
EFFICACY    Antihypertensive
COMMENT     Cilnidipine is metabolized by CYP3A4 with some contribution from CYP2C19.
METABOLISM  Enzyme: CYP3A4 [HSA:1576]; CYP2C19 [HSA:1557]
INTERACTION  
BRITE       Therapeutic category of drugs in Japan [BR:br08301]
             2  Agents affecting individual organs
              21  Cardiovascular agents
               214  Antihypertensives
                2149  Others
                 D10525  Valsartan and cilnidipine
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01925  Renin-angiotensin system inhibitor
               D10525  Valsartan and cilnidipine
              DG03231  Antihypertensive
               D10525  Valsartan and cilnidipine
             Metabolizing enzyme substrate
              DG01639  CYP2C19 substrate
               D10525  Valsartan and cilnidipine
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10525  Valsartan and cilnidipine
            Drug classes [BR:br08332]
             Cardiovascular agent
              DG03231  Antihypertensive
               D10525  Valsartan and cilnidipine
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10525
DBLINKS     PubChem: 254741487
///
